Patent application number | Description | Published |
20080307438 | STATUS HUB USED BY AUTONOMIC APPLICATION SERVERS - A method for serving applications including receiving a component status publication and acquiring a client request. The component status publication can specify a usage level for an application component. A server response for the client request can be selected from among a multitude of possible server responses based at least in part upon the component status publication. Each possible server response can differentially utilize application components. The client request can be response to by conveying the selected server response. | 12-11-2008 |
20090083749 | RESTRICTING RESOURCES CONSUMED BY GHOST AGENTS - One aspect of the present invention can include a method for restricting resources consumed by ghost agents. The method can include the step of associating a ghost agent with a host. A resource utilization value can be ascertained for the ghost agent and the host combined. The ascertained resource utilization value can be compared with a usage threshold. A determination can be made as to whether operations of the ghost agent are to be executed based upon the previous comparison. | 03-26-2009 |
20090106420 | GHOST AGENTS FOR APPLICATION DOMAINS WITHIN A GRID ENVIRONMENT - A method for evaluating system behavior of an application domain within a grid environment can include the step of identifying a host software object within the application domain. A software object can be associated with the host software object. Within the associated software object, host actions can be replicated. Replicated actions can be recorded. The host software object can move from one grid within the grid environment to a different grid. The associated software object can responsively move within the grid environment in accordance with movement of the host software object. | 04-23-2009 |
20090112565 | TESTING APPLICATIONS WITHIN A GRID ENVIRONMENT USING GHOST AGENTS - A testing method including the step of identifying multiple hosts located within multiple grids of a grid environment, wherein each host is a software object. A ghost agent can be associated with each identified host. Actions of the host can be replicated within each ghost agent. Data relating to the replicated actions can be recorded. Test input can be generated from the recorded data. Tests can be conducted within the grid environment using the test input. | 04-30-2009 |
20090113190 | GATHERING OPERATIONAL METRICS WITHIN A GRID ENVIRONMENT USING GHOST AGENTS - A method for gathering operational metrics can include the step of identifying a host within a grid environment, wherein the host can be a software object. A ghost agent can be associated with the host. The ghost agent can replicate actions of the host. Operational metrics for at least a portion of the replicated actions can be determined. The operational metrics can be recorded. The host can move within the grid environment. The ghost agent can responsively move in accordance with movement of the host. | 04-30-2009 |
20090113395 | VALIDATING SOFTWARE IN A GRID ENVIRONMENT USING GHOST AGENTS - A validation method can include the step of identifying a host within a grid environment, wherein the host is a software object. A ghost agent can be associated with the host, where the ghost agent can move within the grid environment. The actions of the host can be replicated by the ghost agent. Data related to the replicated actions can be compared with validation data. Validation output can be generated based upon the comparison. | 04-30-2009 |
20090119544 | GHOST AGENTS WITHIN A GRID ENVIRONMENT - A method for evaluating system behavior within a grid environment can include the step of identifying a host software object, wherein the host software object includes a user object, an application, and/or a process. The software object can be associated with the host software object. The host actions of the host software object can be replicated within the associated software object. Replicated actions can be recorded. The host software object can move from one grid within the grid environment to a different grid. In response to the moving of the host software object, the associated software object can move from the one grid to the different grid. | 05-07-2009 |
Patent application number | Description | Published |
20090004213 | COMBINATION THERAPY USING ACTIVE IMMUNOTHERAPY - The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof. | 01-01-2009 |
20090123489 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 05-14-2009 |
20090136528 | NOVEL IMMUNOGENIC EPITOPE FOR IMMUNOTHERAPY - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 05-28-2009 |
20090148400 | COMPOSITION OF TUMOUR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumour immune responses against colorectal cancer. | 06-11-2009 |
20100158931 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 06-24-2010 |
20110002963 | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas. | 01-06-2011 |
20110117117 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 05-19-2011 |
20120141517 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 06-07-2012 |
20130004456 | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas. | 01-03-2013 |
20130309193 | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas. | 11-21-2013 |
20140271692 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 09-18-2014 |
20150125477 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 05-07-2015 |
20150125478 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 05-07-2015 |
Patent application number | Description | Published |
20120289657 | FUNCTIONAL MATERIALS WITH CONTROLLABLE VISCOSITY - The present invention relates to an innovative method for controlling the viscosity of, for example, adhesives or coating formulations. The method for controlling viscosity allows very rapid thermoplastic curing of a formulation even at room temperature and a significant reduction in the viscosity at higher temperatures, thereby regaining the capacity for simple processing and allowing, for example, the originally bonded substrates to be separated from one another again with ease. A particular aspect in this context is that a plurality of cycles of thermoplastic curing and a significant reduction in the viscosity are possible with the present system. | 11-15-2012 |
20120309895 | FUNCTIONAL MATERIALS WITH REVERSIBLE CROSSLINKING - The present invention relates to an innovative method for the reversible crosslinking of, for example, adhesives or coating materials. The reversible crosslinking method allows very rapid crosslinking even at room temperature and undoing of the crosslinks at higher temperatures, thereby regaining the capacity for thermoplastic processing and allowing the originally bonded substrates to be separated from one another again with ease. A particular aspect in this context is that a plurality of cycles of crosslinking and undoing of the crosslinks are possible with the present system. | 12-06-2012 |
20130172480 | FUNCTIONAL MATERIALS HAVING A CONTROLLABLE VISCOSITY OR REVERSIBLE CROSSLINKING VIA AZA DIELS-ALDER REACTIONS WITH BISHYDRAZONES OR CONJUGATED BIS-SCHIFF BASES - The present invention relates to innovative materials which are reversibly crosslinkable by means of a thermoreversible mechanism and/or whose viscosity is reversibly adjustable. Through the use of bishydrazones or conjugated bis-Schiff bases as diene components in aza-Diels-Alder reactions, functional materials are generated that feature controllable viscosity and/or reversible crosslinking. | 07-04-2013 |
20130289164 | IMPACT-MODIFIED REACTION RESIN - The present invention comprises a novel formulation for marking trafficways, for example roads, which when compared with the prior art have improved mechanical properties and improved heat resistance during curing. The invention also relates to improved reactive resins for other applications than roadmarkings. The present invention in particular relates to reactive resins which comprise core-shell particles. | 10-31-2013 |
20130303678 | MATERIALS HAVING A CONTROLLABLE DEGREE OF CROSSLINKING - The present invention relates to innovative materials which can be crosslinked by means of two different crosslinking mechanisms, the first crosslinking mechanism being an irreversible crosslinking. The second crosslinking mechanism is a thermoreversible mechanism. | 11-14-2013 |
20140121327 | POLYMER POWDER FOR PRODUCING THREE-DIMENSIONAL OBJECTS - The invention relates to the use of a powder made of a polymer, which of two or more components with functionalities suitable for Diels-Alder reactions, or of a powder mixture (dry blend) made of powders respectively of at least one of the reactive components, where these together enter into the Diels-Alder reaction with one another and are capable of a retro-Diels-Alder reaction, in a rapid-prototyping process. | 05-01-2014 |
20140128536 | LOW-ODOUR (METH)ACRYLIC REACTION RESINS - The present invention relates to an innovative (meth)acrylic reactive resin which cures with low odour or odourlessly. The present invention relates more particularly to reactive resins comprising high-boiling, reactive (meth)acrylic monomers from the group of the polar, cyclically substituted esters of (meth)acrylic acid, more particularly glycerol acetal, ketal or carbonate methacrylates. These new components are used as substitutes for MMA, which represents the major part of the odour nuisance in the existing, prior-art reactive resin systems. Using these new components it is possible to obtain resin formulations which have glass transition temperatures similar to, and properties comparable with, MMA-based resins. The innovative reactive resins are able in addition to exhibit more rapid curing than prior-art MMA-based systems. Reactive resins for the purposes of the invention are reactive monomer mixtures or mixtures of monomers and polymers that when used as a 2-component system can be readily cured. | 05-08-2014 |
20140163165 | LOW MOLECULAR WEIGHT PRODUCTS AND USE THEREOF AS REVERSIBLE OR PERMANENT LOW-TEMPERATURE CROSSLINKING AGENT IN DIELS-ALDER REACTIONS - The invention relates to low molecular mass products and to the use thereof as reversible or permanent low-temperature crosslinkers in Diels-Alder reactions. | 06-12-2014 |
20140323001 | PSEUDOTHERMOPLASTIC, SELF-CROSSLINKING COMPOSITES - In the present process, reversibly crosslinking composites or storage-stable prepregs are produced by means of a hetero Diels-Alder reactions (HDA,) for example of PMMA polymers. At slightly elevated temperature, these prepregs can be reversibly decrosslinked again by a retro hetero Diels-Alder reaction so that they become moldable. The back-reaction to products which are again crosslinked or high molecular weight then takes place at room temperature. | 10-30-2014 |
20140323648 | PHOTO-INDUCED CROSSLINKING OF DOUBLE BOND-CONTAINING POLYMERS BY MEANS OF A PERICYCLIC REACTION - The present invention relates to a novel method for photoinduced crosslinking of, for example, adhesives or coating compositions. | 10-30-2014 |